Is Race Oncology Limited a good investment? Race Oncology Limited (RAC.AX) is currently trading at 1.45 AUD.
Earnings Schedule: Race Oncology Limited is expected to release its next earnings report on March 3, 2027. The market consensus estimate for Forward EPS is -0.10.
No, it does not currently pay a dividend.
Race Oncology Limited is classified as a Stock. You can compare it against 2 other assets in the "Related Symbols" list on this page.
The next earnings date is projected to be March 3, 2027. The company currently has a trailing EPS of -0.06.
Racura Oncology Ltd operates as a clinical-stage biopharmaceutical company in Australia. It develops RC220, a formulation of (E,E)-bisantrene, which is in Phase III clinical trial for the treatment of acute myeloid leukemia; Phase Ia/b clinical trial for the treatment of epidermal growth factor receptor-mutated non-small cell lung cancer; and Phase Ia/b clinical trial for the treatment of solid tumor cancers. The company was formerly known as Race Oncology Limited and changed its name to Racura Oncology Ltd in December 2025. Racura Oncology Ltd was incorporated in 2011 and is headquartered in Sydney, Australia.
Community Discussion